OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
Vipul Bhatia, Nikhil Kamat, Tiffany E. Pariva, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 55
Vipul Bhatia, Nikhil Kamat, Tiffany E. Pariva, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 55
Showing 1-25 of 55 citing articles:
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Martin Bakht, Himisha Beltran
Nature Reviews Urology (2024)
Closed Access | Times Cited: 16
Martin Bakht, Himisha Beltran
Nature Reviews Urology (2024)
Closed Access | Times Cited: 16
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors
Salma Khan, Yeonjoo Choi, Mysore S. Veena, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 3
Salma Khan, Yeonjoo Choi, Mysore S. Veena, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 3
Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles
Paola A. Castagnino, Derick A. Haas, Luca Musante, et al.
Cancer Biology & Therapy (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 2
Paola A. Castagnino, Derick A. Haas, Luca Musante, et al.
Cancer Biology & Therapy (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 2
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
William K. Kelly, Daniel C. Danila, Chia‐Chi Lin, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 76-89
Open Access | Times Cited: 29
William K. Kelly, Daniel C. Danila, Chia‐Chi Lin, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 76-89
Open Access | Times Cited: 29
Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression
Yunna Chen, Qianqian Zhou, Zongfang Jia, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 9, pp. 3834-3854
Open Access | Times Cited: 14
Yunna Chen, Qianqian Zhou, Zongfang Jia, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 9, pp. 3834-3854
Open Access | Times Cited: 14
Future perspectives on engineered T cells for cancer
Avery D. Posey, Regina M. Young, Carl H. June
Trends in cancer (2024) Vol. 10, Iss. 8, pp. 687-695
Open Access | Times Cited: 14
Avery D. Posey, Regina M. Young, Carl H. June
Trends in cancer (2024) Vol. 10, Iss. 8, pp. 687-695
Open Access | Times Cited: 14
The potential and promise for clinical application of adoptive T cell therapy in cancer
Yinqi Li, Yeteng Zheng, Taiqing Liu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 12
Yinqi Li, Yeteng Zheng, Taiqing Liu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 12
Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies
Samir Zaidi, Jooyoung Park, Joseph M. Chan, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 28
Open Access | Times Cited: 10
Samir Zaidi, Jooyoung Park, Joseph M. Chan, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 28
Open Access | Times Cited: 10
What influences the activity of Degrader−Antibody conjugates (DACs)
Yaolin Guo, Xiaoxue Li, Yang Xie, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116216-116216
Closed Access | Times Cited: 9
Yaolin Guo, Xiaoxue Li, Yang Xie, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116216-116216
Closed Access | Times Cited: 9
A novel prostate cancer-specific fluorescent probe based on extracellular vesicles targeting STEAP1 applied in fluorescence guided surgery
Jian‐Xuan Sun, Qi‐Dong Xia, Jin‐Zhou Xu, et al.
Journal of Controlled Release (2025) Vol. 380, pp. 199-218
Open Access | Times Cited: 1
Jian‐Xuan Sun, Qi‐Dong Xia, Jin‐Zhou Xu, et al.
Journal of Controlled Release (2025) Vol. 380, pp. 199-218
Open Access | Times Cited: 1
Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy
Bohan Zhang, Jiawen Wu, Hua Jiang, et al.
Cells (2025) Vol. 14, Iss. 5, pp. 320-320
Open Access | Times Cited: 1
Bohan Zhang, Jiawen Wu, Hua Jiang, et al.
Cells (2025) Vol. 14, Iss. 5, pp. 320-320
Open Access | Times Cited: 1
Knowledge mapping of application of image-guided surgery in prostate cancer: a bibliometric analysis (2013–2023)
Na Zeng, Jian‐Xuan Sun, Chen‐Qian Liu, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 6
Na Zeng, Jian‐Xuan Sun, Chen‐Qian Liu, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 6
T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer
Julia Palecki, Amman Bhasin, Andrew Bernstein, et al.
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 6
Julia Palecki, Amman Bhasin, Andrew Bernstein, et al.
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 6
Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study
Frédéric Pouliot, Fred Saad, Étienne Rousseau, et al.
Journal of Nuclear Medicine (2024), pp. jnumed.124.268020-jnumed.124.268020
Closed Access | Times Cited: 6
Frédéric Pouliot, Fred Saad, Étienne Rousseau, et al.
Journal of Nuclear Medicine (2024), pp. jnumed.124.268020-jnumed.124.268020
Closed Access | Times Cited: 6
The Immune Microenvironment in Prostate Cancer: A Comprehensive Review
René Novysedlák, Miray Guney, Majd Al Khouri, et al.
Oncology (2024), pp. 1-25
Open Access | Times Cited: 6
René Novysedlák, Miray Guney, Majd Al Khouri, et al.
Oncology (2024), pp. 1-25
Open Access | Times Cited: 6
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Olivier Nolan-Stevaux, Cong Li, Lingming Liang, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 90-103
Closed Access | Times Cited: 15
Olivier Nolan-Stevaux, Cong Li, Lingming Liang, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 90-103
Closed Access | Times Cited: 15
Cancer immunotherapy focusing on the role of interleukins: A comprehensive and updated study
Mahmoud Samadi, Amin Kamrani, Hadi Nasiri, et al.
Pathology - Research and Practice (2023) Vol. 249, pp. 154732-154732
Closed Access | Times Cited: 13
Mahmoud Samadi, Amin Kamrani, Hadi Nasiri, et al.
Pathology - Research and Practice (2023) Vol. 249, pp. 154732-154732
Closed Access | Times Cited: 13
Emerging Immunotherapy Approaches for Treating Prostate Cancer
Lingbin Meng, Yuanquan Yang, Amir Mortazavi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 14347-14347
Open Access | Times Cited: 13
Lingbin Meng, Yuanquan Yang, Amir Mortazavi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 14347-14347
Open Access | Times Cited: 13
Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects
Yueyao Jiang, Chengran Wang, Chuancheng Zu, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 9459-9486
Open Access | Times Cited: 5
Yueyao Jiang, Chengran Wang, Chuancheng Zu, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 9459-9486
Open Access | Times Cited: 5
Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer
Peter Zanvit, Dewald van Dyk, Christine Fazenbaker, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 22
Open Access | Times Cited: 12
Peter Zanvit, Dewald van Dyk, Christine Fazenbaker, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 22
Open Access | Times Cited: 12
Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches
Adam Khorasanchi, Feng Hong, Yuanquan Yang, et al.
Cancer Drug Resistance (2025)
Open Access
Adam Khorasanchi, Feng Hong, Yuanquan Yang, et al.
Cancer Drug Resistance (2025)
Open Access
Unleashing the power of peptides in prostate cancer immunotherapy: mechanism, facts and perspectives
Xiaoya Li, Fang Yang, Meijing Wang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Xiaoya Li, Fang Yang, Meijing Wang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
T-cell Engagers in Prostate Cancer
Chadi Hage Chehade, Zeynep İrem Özay, Micah Ostrowski, et al.
European Urology (2025)
Closed Access
Chadi Hage Chehade, Zeynep İrem Özay, Micah Ostrowski, et al.
European Urology (2025)
Closed Access
The application of emerging immunotherapy in the treatment of prostate cancer: progress, dilemma and promise
Jizhong Che, Yuanyuan Liu, Yangyang Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Jizhong Che, Yuanyuan Liu, Yangyang Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Interleukin expression patterns and immune cell infiltration in prostate adenocarcinoma: Implications for recurrence risk
J Zhang, Cong Huang, Xuming Wang, et al.
International Journal of Immunopathology and Pharmacology (2025) Vol. 39
Open Access
J Zhang, Cong Huang, Xuming Wang, et al.
International Journal of Immunopathology and Pharmacology (2025) Vol. 39
Open Access
